Shares of OPKO Health (OPK) surged 5.52% in pre-market trading on Friday, following the company's impressive fourth-quarter 2024 results and significant progress in its pharmaceutical pipeline.
The biopharmaceutical company reported a net income of $14 million, or $0.01 per diluted share, for the fourth quarter of 2024, a notable improvement from a net loss of $66.5 million in the same period last year. This positive turnaround was driven by several key factors:
1. Strong growth in the Pharmaceutical segment, with revenue increasing by 39% year-over-year to $80.5 million, boosted by higher product sales and milestone payments from collaborations.
2. Significant progress in OPKO's proprietary ModeX pipeline, with two programs entering Phase 1 clinical trials, including a tetraspecific antibody (MDX-2001) for solid tumors and a nanoparticle vaccine for Epstein-Barr Virus (EBV) in collaboration with Merck.
3. Improved financial position and capital structure, supported by a $50 million upfront payment from the Merck collaboration and the sale of GeneDx, allowing OPKO to fund its pipeline advancement and initiate share buybacks.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。